首页
探索
nav.journalClub
趋势
更多
synapse
⌘+K
语言
简体中文
简体中文
March 3, 2026
Open Access
Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report
JL
J. Lapins
NR
Niki Radros
Karolinska University Hospital
KS
Karina Schultz
Karolinska University Hospital
See all
Key Points
Resolution of high-risk basal cell carcinoma was achieved using eribulin, a microtubule-targeting agent.
The treatment resulted in significant tumor shrinkage, showcasing eribulin's potential in BCC management.
Observational analysis provided insights into chemotherapy options for managing challenging cases of basal cell carcinoma.
Highlights the need for further exploration of microtubule-targeting agents in the treatment of skin cancers.
Read Full Paper
with AI
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Mark Helpful
Like
Save
Bookmark
Relay
Share
View Full Paper
Cite This Study
Copy
Lapins et al. (Tue,) studied this question.
synapsesocial.com/papers/69a7608ec6e9836116a2d68b
https://doi.org/https://doi.org/10.2340/1651-226x.2026.44993
Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report | Synapse